AstraZeneca entered into an agreement to settle US patent infringement litigation with Ranbaxy over Nexium. Under deal terms, Ranbaxy will be allowed to sell a generic version of Nexium under licence from AstraZeneca starting on May 27, 2014. Ranbaxy will have a 180-day period of exclusivity as the only distributor for generic Nexium, and conceded – as part of the agreement – that "all six patents asserted by AstraZeneca in the patent litigation are valid and enforceable." No financial terms of the deal were disclosed.
In addition, the drugmakers entered into an agreement under which Ranbaxy will manufacture a portion of AstraZeneca's US supply of Nexium from May 2010, as well as the treatment's active ingredient from May 2009. Furthermore, the companies signed distribution deals that allow Ranbaxy to be the distributor for authorised generic versions of hypertension compound Plendil and proton pump inhibitor Prilosec in the US.
Ranbaxy CEO Malvinder Singh stated that the agreements with AstraZeneca could earn as much as $1.5 billion in revenue over the next six years
No comments:
Post a Comment